^
7ms
New P2 trial • Metastases
|
Hetronifly (serplulimab) • HLX-53 • Hanbeitai (bevacizumab biosimilar)
8ms
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Aug 2024 --> Dec 2024
Enrollment closed • Enrollment change • Trial primary completion date • Metastases
|
HLX-53
over1year
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
HLX-53
over2years
New P1 trial
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
HLX-53